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Retinoblastoma-binding protein 4 (RBBP4) is a subunit of chromatin remodeling 
factor 1 (CAF-1) and is essential for mammalian oocyte maturation, embryo survival, and 
embryo implantation. RBBP4 also localizes to the chromatin and is a ubiquitously 
expressed nuclear protein. Previous methods used to study this protein include short 
interfacing RNAs (siRNAs) and CRISPR/Cas9. These techniques have limitations such 
as determining an indirect depletion of proteins, may trigger compensatory mechanisms, 
and may not be useful in non-dividing primary cells. A new, acute, and rapid endogenous 
protein depletion technique called Trim-Away, can overcome these limitations. Trim-
Away is also widely applicable since it can be used with many off-the-shelf reagents. 
Trim-Away utilizes the TRIM21-antibody interaction within the cytosol and the 
ubiquitin-proteasome pathway (UPP) to target and degrade a protein of interest. Studying 
RBBP4 using Trim-Away can offer insight into possible new functions of RBBP4 and its 
maternal effect, and increase the knowledge on a new, acute, and endogenous protein 
depletion technique. Here we report that, RBBP4 is required for proper blastocyst 
development and RBBP4 is more abundant in MII oocytes than GVBD oocytes. We also 
report that the loss of RBBP4 hinders RNA synthesis and causes cell death in later stages 
v 
of embryo development. While our Trim-Away methodology can deplete RBBP4 as early 
as the 2-cell stage in embryos, our oocyte Trim-Away protocol needs to be optimized. 
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A. Mammalian Oocyte Maturation 
William Harvey, M.D. (1578-1657), once stated “omne vivum ex ovo” or “all 
living things come from eggs,” which summarizes the importance of the oocyte in 
reproduction [1]. The maturation of a mammalian immature oocyte refers to the period of 
progression from the first to second meiotic arrest, ensures the capability of fertilization, 
and is the last phase of oogenesis [2, 3]. The oocyte needs to provide the developing 
embryo with the majority, if not all, of the molecular factors it will need until the 
embryonic genetic program is activated [1]. The maturation process involves tightly 
choreographed movements of chromosomes, activity of regulators and inhibitors, a high 
transcription rate, and many other factors through a specialized cell division process 
called meiosis [2, 4, 5]. Meiosis is unique to gametes (oocytes and sperm) and occurs 
during oocyte maturation, following steps for metaphase I (MI)/metaphase II (MII) 
spindle formation, the spindle assembly checkpoint (SAC), and chromosome segregation 
[4, 6].Meiosis will progress continuously and will take about 12 hours in comparison to 
the 1 hour that mitosis does [4].  
Normally, immature oocytes are arrested at the diplotene (fourth) stage of 
prophase I, also known as the germinal vesicle (GV) stage [7]. The GV is also known as 
the nucleus during the prophase stage [8]. In vivo, meiotic arrest is removed only after 
sexual maturity is reached and will differ between mammalian species [4]. During 
follicular growth within a female mouse, many ovarian follicles and cells within them 
respond to the luteinizing hormone (LH) surge for regulation of oocyte meiotic cell cycle 
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resumption[4]. This is restricted to oocytes which have reached full-size[7]. Once meiosis 
resumes, the disassembly of the GV/nuclear membrane called germinal vesicle 
breakdown (GVBD), occurs as the first morphological manifestation, and allows further 
maturation in the meiosis I process [4, 8]. Meiosis I will last for about 6-12 hours in mice 
going through stages such as prophase, prometaphase, MI, anaphase, telophase, and MII 
(Figure 1)[6]. During meiosis, oocytes undergo two consecutive asymmetric cytoplasm 
and symmetric nuclear divisions without an intervening S-phase (the DNA replication 
stage), to become germ cells which then contain half of the chromosomes previously 
present [9, 10]. At the MII stage, there is a division which consists of a large oocyte and a 
small polar body, a non-functional cell-like structure that degrades soon after it is 
extruded and will remain within the perivitelline space [7, 8]. This first polar body will be 
called polar body 1 (PBI) and after fertilization there will be a second polar body 
extruded called polar body 2 (PBII) [4]. The polar bodies extruded will include ¾ of 
supernumerary, or excess, chromosomes overall [11]. To ensure the success of offspring, 
appropriate chromosome segregation should take place during this process[12]. 
Pomerantz and Dekel make a point to state that any misstep within meiosis can cause 




Fig 1. Mouse Oocyte Maturation (Adapted from[6])  
Under in vitro maturation conditions, the maturation of the mouse oocyte from the GV 
stage to the MII stage is completed in around 12h, with GVBD occurring around 2h and 




Since germ cells are by far larger than somatic cells (mouse oocytes are around 70 
µM while mouse epidermal cells are around 9 µM) they require additional steps of 
cellular reorganization such as spindle migration to the cortex via the microtubule 
organizing center (MTOC), the spindle assembly checkpoint (SAC), the mitogen-
activated protein kinase (MAPK) pathway, and the ubiquitin proteasome pathway 
(UPP)[4, 6, 9, 13, 14]. The UPP plays an important role in protein degradation within 
living cells [4]. Röth and colleagues mentioned that the targeted protein of interest (POI) 
relies on recruitment of an E3 ligase for ubiquitination and degradation [15]. E3 ubiquitin 
ligases can be found within he UPP and will tag substrates with polyubiquitin chains for 
degradation. Ubiquitin chains are linked by a unique lysine residue serving as a cellular 
signal that is tagged onto the substrate to be recognized by the proteasome for 
degradation. This E3 ubiquitin ligase also plays an important role in the turnover of 
meiotic and mitotic proteins, and the regulation of the anaphase-promoting 
complex/cyclosome (APC/C) after GVBD for processes such as correct chromosome 
segregation during prometaphase I, and polar body extrusion [4]. 
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When the oocytes reach MII, they will arrest again until fertilization under the 
influence of a cytostatic factor [4, 9]. Fertilization will trigger subsequent completion of 
the meiosis II division. The extrusion of the second polar body follows a calcium 
response from the sperm-egg fusion and opens the opportunity for recombination of 
maternal and paternal homologues to create new genetic combinations in the offspring 
[11]. 
 
B. Fertilization, Maternal Effect Genes, and Preimplantation Embryo Development 
Preimplantation development of a mammalian embryo is considered the point 
from fertilization to the developmental stage of a blastocyst, in utero, and includes many 
morphological changes and lineage differentiations. Understanding the development and 
self-organization of the mouse embryo is important for further cell-reprogramming 
approaches[16].  
Early preimplantation development embryos contain mRNA transcripts that are 
expressed from 2 different origins, maternal and zygotic. Maternal transcripts, also 
known as maternal genes, are deposited in the oocyte from the mother’s genome, while 
the zygotic transcripts originate from the embryo’s genome after fertilization. Maternal 
transcripts rely on post-translational regulatory mechanisms for their expression while 
zygotic transcripts can utilize both transcriptional and post-transcriptional regulatory 
mechanisms. The spatial and temporal expressions of each transcript are different for 
each origin. In mice, at least 30% of these protein-coding genes are expressed in the 
oocyte to embryo transition and can be divided into 3 groups; genes that are expressed 
exclusively from either the maternal or zygotic origin, genes that must be expressed by 
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both origins because of low mRNA stability or a change in spatial expression during 
transition from oocyte to zygote, and genes that can accommodate either maternal or 
zygotic expression [17]. 
Maternal-effect genes (MEGs) are involved in many processes throughout early 
embryo life such as gap-junction communication, DNA methylation status, and zygotic 
gene activation (ZGA). It has been shown with strong evidence that mammalian 
embryonic development depends on oocyte-derived factors which play essential roles as 
early as the zygote stage [18]. After fertilization, both parental genomes recombine and 
form a totipotent zygote through epigenetic remodeling. Before recombination, ZGA, and 
subsequent development, the many maternal factors need to unravel the parental genome 
from the protamines, instead of histones, that arrived in densely packed chromatin. Once 
the chromatin remodeling takes place, the development process can proceed [19]  
Preimplantation development in mice stage takes several days, morphological 
changes, and lineage differentiations [16, 20]. Some of these changes include ZGA 
completed by the post translational modifications of the maternally inherited proteins at 
the 2-cell stage, and include compaction, polarization, and cavitation at the 8-cell stage 
[16, 21]. With further division, 2 distinct cell lineages then start to form: the 
trophectoderm (TE) and the inner cell mass (ICM), each with their own contributions to 
the embryo [16]. Transcription factors promote the different lineages so that the TE 
contributes to the placenta while the ICM contributes to all fetal cells and the embryonic 
yolk sac [16, 20]. The ICM then goes on to have a second lineage decision one day later 
[16]. There is differentiation for either becoming an extraembryonic monolayer that 
meets the blastocoel (primitive endoderm- PrE) or becoming the epiblast (EPI), which 
6 
gives rise to the embryo proper [20]. The developmental timeline for mouse 
preimplantation embryos can be seen in Figure 2. 
 
 
     
Fig 2. Mouse Embryo Development [20] 
At embryonic day 0.5 (E0.5), fertilization, both the maternal and paternal nuclei are 
present and a total of 2 polar bodies have been extruded. At E1.5 the polar bodies start to 
degrade and the cell divides into the 2-cell and 4-cell stages while ZGA occurs. At E2.5 
the embryo goes through compaction and polarization processes as it develops from the 
8-cell stage to the morula stage. At E3.5, the blastocoel is present, and the embryo goes 
through cavitation creating the TE and ICM. At E4.5 the ICM is differentiated into the 




C. Retinoblastoma-Binding Protein 4 (RBBP4) 
In addition, retinoblastoma-binding protein 4 (RBBP4) is an essential protein for 
oocyte maturation and embryo development that localizes to chromatin and functions as a 
small subunit of the chromatin-remodeling factor 1 (CAF-1) [22, 23]. CAF-1 assembles 
nucleosomes in a replication-dependent manner (Miao et al., 2020). RBBP4 loads 
histones H3 and H4 (specifically H3K4, H3K8, H4K12, and H4K16) onto newly 
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replicated DNA to institute nucleosome assembly [22, 23]. While assisting CAF-1, 
RBBP4 can also be called chromatin-remodeling factor RBAP48 [23].  
RBBP4 localizes to chromatin and is a ubiquitously expressed nuclear protein 
belonging to the Trp-Asp repeating protein subunit, also known as the WD-40 family [22, 
23]. Within all stages of embryo development, RBBP4 can be detected within the nucleus 
of the cell [23]. The localization via immunofluorescence can be seen in Figure 3. It is 
also found in many other protein complexes such as the histone deacetylase complex 
(HDAC), the nucleosome remodeling and deacetylase complex (NuRD), and the 
polycomb repressive complex 2 (PRC2)[24-26]. HDAC removes acetyl groups from 
specific amino acids on histones while NuRD and PRC2 are involved in the regulation of 
gene expression and lineage commitment [24, 25]. RBBP4 is a subunit in each protein 
complex that aids in their regulation of chromatin structure and gene transcription [23]. In 
addition, RBBP4 is involved in many other biological processes such as cell proliferation, 
apoptosis, nuclear transport, cellular senescence, DNA repair, tumorigenesis, and age-





Fig 3. RBBP4 Signal from GV Oocytes to 2-cell Embryos. 
IF was conducted on oocytes and embryos. There is a strong nuclear signal for RBBP4 at 
the GV oocyte stage, zygote embryo stage, and 2-cell embryo stage. At the MII oocyte 




During mammalian embryo development, RBBP4 is essential for proper 
segregation of the ICM and TE and for proper implantation. Loss of this protein within 
the mouse model causes reduced or absent ICM, severe apoptosis, hyperacetylated 
histones, and preimplantation lethality [23]. During mouse oocyte maturation, histone 
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deacetylation is regulated by multiple pathways. RBBP4 regulates HDACs along with 
retinoblastoma binding protein P46 (RBBP7), but their functions do not overlap. While 
these two proteins work together for successful completion of meiosis I, without the 
docking site for HDAC provided by RBBP4, there is abnormal bipolar spindle formation 
at MI with PBI extrusion defects, chromosome misalignment, and aneuploidy at MII 
[22]. Although great discoveries were made within both Balboula and Miao using 
techniques such as short interfering RNAs (siRNAs), morpholinos, and CRISPR/Cas9, 
each study saw limitations within their models; Balboula and colleagues could not 
deplete RBBP4 fully within oocytes while Miao et al., 2020 could only study their 
RBBP4 homozygous knockout from E4.0 to E7.5 [22, 23]. 
 
D. Trim-Away and TRIM21  
Within current and past protein function studies, scientists have used methods which 
target the production of their target protein, including techniques such as CRISPR/Cas9 
and RNA Interface (RNAi) [31]. Both methods work on the DNA or RNA level, may 
trigger compensatory mechanisms and may not be useful in non-dividing primary cells 
[32-34]. In both methods, protein depletion if indirect and dependent on the turnover of 
the protein, therefore long-lived proteins may take more time to deplete or may be 
resistant to DNA and RNA-targeting depletion [35]. There are also limitations of gene 
activation and loss of function phenotypes when dealing with essential genes [34]. 
Overall, there is a great need for a new method that will overcome these limitations by 
targeting the proteins directly and Trim-Away can be the answer we are looking for.   
10 
Trim-Away is a posttranslational, acute, and rapid endogenous protein depletion 
technique. It utilizes the tripartite motif-containing protein 21 (TRIM21)-antibody 
interaction within the cytosol to target a POI. When using Trim-Away, the POI does not 
need to be modified before degradation, proteins are degraded within minutes of 
application, and it allows the study of various protein functions in diverse mammalian 
cell types. In addition, Trim-Away is widely applicable since it can be used with many 
off-the-shelf reagents [35]. Trim-Away, based on the levels of target protein within the 
cell, TRIM21, and the amount of antibody applied, can be effective for around 3-4 days 
[15]. Trim-Away is about 2-12 times faster than auxin-inducible protein degradation and 
reduces the time of protein degradation compared to using morpholinos [12, 36]. 
Trim-Away requires the use of TRIM21 mRNA and a specific antibody to the 
POI that recognizes its native conformation [33].  The mRNA and antibody will be 
microinjected into a single cell or electroporation into bulk cell populations at certain 
time points for protein depletion to occur [35]. Microinjection, a microsurgical procedure 
conducted on a single cell, is a more direct approach and ensures delivery in all cells that 
will be treated [37, 38]. For Trim-Away to occur, the injected antibody binds to the POI 
and injected TRIM21 detects the antibody by binding to its fragment crystallizable region 
(Fc region) [39]. After all 3 of the components are bound as the protein-antibody-
TRIM21 complex, it is ubiquitinated and is rapidly degraded by the proteasome [15, 35]. 
TRIM21 is an E3 ubiquitin ligase, multidomain, trimeric protein found in the 
intracellular antibody-mediated proteolysis pathway and is a type I interferon-stimulated 
gene [39-41]. A type I interferon is an “inducible cytosolic protein that binds to 
antibodies with high affinity”, can be called an antibody receptor, and substantially 
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upregulates TRIM21 [39, 41]. TRIM21 contains a Ring-type E3 ubiquitin ligase domain 
(RING domain), a B-box domain, and “a coiled-coil domain that is thought to form an 
antiparallel homodimer”, two of the same proteins [39, 42]. It also contains a carboxyl-
terminal (C-terminal) PRYSPRY domain [39, 43]. Two copies of this domain allow for 
simultaneous binding of heavy chains of an antibody [39]. When the RING domain 
activates, it recruits the ubiquitin proteasome system to the antibody bound pathogen for 
the automatic creation of ubiquitin chains [39, 42, 43]. These chains have two functions: 
to simulate immune responses and cause proteasome-mediated destruction [39, 43].  
Classical cell surface antibody receptors are very specific in isotype and subclass, 
unlike TRIM21. TRIM21 binds to all subclasses of Rb IgG (Rb IgG1, Rb IgG2, Rb IgG3, 
Rb IgG4) with similar affinities and its binding is highly conserved [39]. This means that 
mouse and human TRIM21 will bind to antibodies of other mammals [32]. TRIM21 is 
the highest Rb IgG antibody receptor in humans and can also bind to IgA and IgM, but 
the bond will not be as strong [39]. To use TRIM21 in an oocyte for protein depletion 
there is a three-step strategy written by Clift and colleagues: “first, the introduction of 
exogenous TRIM21; second, the introduction of an antibody against the protein of 
interest; and third, TRIM21-mediated ubiquitination followed by degradation of the 
antibody-bound protein of interest” (Figure 4) [35].  
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Fig 4. Trim-Away Schematic [35] 
TRIM21, endogenous or overexpressed, interacts with an antibody for the degradation of 
an endogenous POI. The injected antibody for the POI enters the cytosol where the 
endogenous protein and TRIM21 reside. Once all 3 components are bound together, the 
POI will be tagged with a ubiquitin chain which then will be dragged to the proteasome 





E. Aim of Study  
Based on previous studies, we know RBBP4 is essential for mammalian oocyte 
maturation, embryo survival, and embryo implantation. These studies used genetic 
techniques such as short interfering RNAs (siRNAs), morpholinos, and CRISPR/Cas9, 
which provided limitations within their experiments. Miao et al., 2020 was conducted 
through a collaboration between the Mager lab and our lab, by using a knockout RBBP4 
mouse model. The limitation we saw was breeding a heterozygous female with 
13 
heterozygous males. Maternally loaded RBBP4 was present within these knockout 
embryos and was not degraded until after flushing embryos from the uterine horns and 
culturing overnight to E4.0. Having a knockout (mutant) sperm fertilize a mutant oocyte 
for a homozygous knockout, caused embryo lethality after E7.5 and the later depletion of 
Rbbp4 did not allow for early embryo development to be studied in-depth. In additions, 
MEGs were not explored during Miao’s study. Since the Rbbp4 gene is highly expressed 
during oogenesis and oocyte maturation, we wanted to extend our studies to define the 
role of RBBP4 within oocyte maturation and early embryo development. Within this 
current study, we will be using Trim-Away for the rapid depletion of RBBP4 to study its 
effects on oocyte maturation and early embryo development. Studying RBBP4 using 
Trim-Away can offer insight into possible new functions of RBBP4 and its maternal 







MATERIALS AND METHODS 
A. Ethics statement and animal use 
C57BL/6 RBBP4 wildtype (WT) mice were used for all experimental procedures 
and methods approved by the Institutional Animal Care and Use Committee of the 
University of Massachusetts Amherst (2017- 0071). All mice were maintained on 
provided water ad libitum under a 12-hour (h) light: dark cycle. Proper training was 
obtained for euthanasia of mice using the approved method of cervical dislocation via Dr. 
J. Paul Spurlock, Director of Animal Care and Attending Veterinarian at the University 
of Massachusetts Amherst.   
B. Oocyte and zygote collection  
Fully grown GV oocytes were collected from 6–8-week-old female mice that 
were injected intraperitoneally (IP) with 0.3 mL of pregnant mares’ serum gonadotropin 
(PMSG) 45-46h previously. Ovaries were removed and placed into a 1X cilostamide 
(Cat#C7971-5MG) solution containing EmbryoMax M2 Medium with Phenol Red 
(Millipore, MR-015-D) for cell cycle arrest. Antral follicles were punctured using a 
sterile 26-gauge, 1 mL needle and the oocytes were collected for cumulus cell removal. 
The cumulus cells were removed with a pulled 1.0mm OD tip from Fisher Scientific.  
Mature ovulated MII oocytes were collected from 6–8-week-old female mice that 
were injected IP with 0.3 mL of human chorionic gonadotropin (hCG) 48h after PMSG 
treatment. Ovaries and oviducts were removed 18h and placed into M2 medium. MII 
arrested oocytes were collected from the ampulla of the oviduct and placed into 
15 
EmbryoMax M2 Medium with Hyaluronidase (Millipore, MR-051-F) for 3-5 minutes. 
Cumulus cells were removed with a pulled and fire polished 1.5mm OD tip.  
Zygotes were collected from 6–8-week-old female mice that were injected IP with 
0.3 mL of hCG and directly mated with double studs 48h after PMSG treatment. Ovaries 
and oviducts were removed 18h later and placed into M2 medium. Zygotes were 
collected from the ampulla of the oviduct and placed into M2 Medium with 
Hyaluronidase for 5 minutes. Cumulus cells were removed with a pulled and fire polished 
1.5mm OD tip.    
C. mRNA preparation 
All plasmids used to generate mRNA were purchased from Addgene and include 
pGEMHE-mEGFP-mTRIM21, pGEMHE-mCherry-mTRIM21, pGEMHE-H2B-mEGFP, 
and pGEMHE-mEGFP-Map4 [44]. Each plasmid was streaked on an LB agar plate for 
overnight culture in 37ºC incubator using sterile inoculating loops. The next morning, 
single colonies were collected for liquid culture in LB with ampicillin overnight in an 
incubating minishaker at 37ºC. Plasmids were isolated the following afternoon using a 
QIAprep Spin Miniprep Kit (Qiagen, 27104). Each plasmid was validated by cutting the 
plasmid twice with buffers and enzymes from New England BioLabs [45]. Buffers and 
enzymes used include CutSmart Buffer (NEB, B7204S), 3.1 Buffer (NEB, B7203S), AscI 
enzyme (NEB, R0558S), EcoRI enzyme (NEB, R0101S), HindIII enzyme (NEB, 
R0104S), SwaI enzyme (NEB, R0604S), and AgeI enzyme (NEB, R0552S). A 1% 
agarose gel was run to confirm these cuts. All agarose gels contain Ethidium Bromide 
(Millipore-Sigma, 1239-45-8) for DNA and RNA detection, unless otherwise stated. The 
enzyme used to cut each respective plasmid can be found in Table 1. After validation, the 
16 
plasmids were linearized. Capped mRNA was then synthesized through in vitro 
transcription via a mMESSAGE mMACHINE T7 Kit (Invitrogen, AM1344). Enzymes 
AscI and SwaI were used for linearization. A 1% agarose gel was run to confirm the 
linearization. The enzymes used for each respective plasmid can be found in Table 2. All 
plasmids were then purified using a Phenol: Chloroform protocol from ThermoFisher 
Scientific using UltraPure Phenol: Chloroform: Isoamyl Alcohol (ThermoFisher, 
15593031). Lastly, all RNA was purified using ethanol precipitation through a 
MEGAclear Transcription Clean-Up Kit (Invitrogen AM1908). The purified RNA was 
diluted using a ratio of either 0.2µL RNA: 3 µL nuclease free water or 0.2µL RNA: 5 µL 
nuclease free water. Concentrations for each RNA extraction were measured on a 
spectrophotometer. A 1% agarose gel was run to confirm all purifications. All plasmids 
used and protocols followed were similar to those from Clift et al., 2017.   
 
mRNA Buffer Enzyme 






pGEMHE-H2B-mEGFP 3.1 HindIII 
SwaI 
pGEMHE-mEGFP-Map4 CutSmart AscI  
AgeI  
Table 1. Plasmid Validation Buffers and Enzymes  
AscI cuts the plasmid at 787 bp. EcoRI cuts the plasmid at 1546 bp. HindIII cuts the 





mRNA Buffer Enzyme 




pGEMHE-H2B-mEGFP 3.1 SwaI 
pGEMHE-mEGFP-Map4 CutSmart AscI  
Table 2. Plasmid Linearization Buffers and Enzymes 






All microinjections were conducted using a Nikon Eclipse Ts2R microscope, 
Eppendorf PiezoXpert, and an Eppendorf TransferMan 4r. All GV oocytes were arrested 
with cilostamide until cell cycle release after all microinjections were completed. All 
injected mRNA and antibody concentrations are listed in Table 3. mRNA was injected 
for freshly collected oocytes and zygotes and incubated for 1-3h for overexpression of 
mRNA injected, in 37 ºC in a humidified atmosphere of 5% CO2, 5% O2 balanced in N2. 
Additionally, GV oocytes were cultured in KSOM with castanoside for 1h to allow for a 
larger perivitelline space. After the allotted culture times, the desired antibody was 
injected into the same cells. Only GV oocytes were treated with cytochalasin B (CB) 
right before microinjection of antibodies. All cells were live imaged for confirmation of 
TRIM21 mRNA injection success. When antibodies were purified, an Amicon Ultra 
0.5mL 100K kit (Millipore, UFC510008), diluted in Dulbecco’s Phosphate Buffered 
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Saline (DPBS) (Gibco, 14190-1440) was used. Both unpurified and purified antibodies 
are stated in each figure where antibodies were used, and antibody purification 
concentrations are listed in Table 3. Figure 5 represents the microinjection technique used 





Antibody  Concentration (mg/mL) 
pGEMHE-mEGFP-
mTRIM21 














300 Anti-MAP4 0.8 
- - Rb IgG 0.35 
Table 3. mRNA and Antibody Microinjection Concentrations 
Where there are 2 concentrations of mRNA listed, the second number is the optimized 
concentration. The mRNA and antibody listed within the same row, do not correlate with 
injection days or to each other. Each mRNA injection was paired with a different 





Fig 5. Microinjection of Zygote  
Before injection of TRIM21 mRNA and antibody, the CellTram 4r Air controlled holding 
pipette (blue arrow) contacts the oocyte or embryo and stabilizes it. Once the cell is in 
place, the injection needle will pierce the zona pellucida (ZP) and cytoplasm for injection 
of TRIM21 mRNA and antibody. The injection needle, controlled by the CellTram 4r Oil 





E. Immunofluorescence (IF) 
Oocytes and zygotes were fixed in 4% paraformaldehyde (PFA) either for 20 
minutes at room temperature or overnight in 4 ºC and washed in 24 well plate for 10 
minutes at 100 RPM on a Boekel Flask Dancer in PBS/10% FBS. The cells were then 
permeabilized for 20 minutes in a solution containing PBS/0.3%PVP/0.5% Triton and 
moved to a blocking solution containing PBS/10% FBS/0.1% Triton for 1h. The cells 
were incubated in the appropriate primary antibody for either 1h room temperature or 
overnight in 4 ºC. All primary antibodies except anti-MAP4 were diluted at a ratio of 
1:200 antibody: block including rabbit anti-RBBP4 (Abcam, ab79416), mouse anti-H2B 
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(Abcam, ab52484), rabbit anti-Histone4K5 + K8 + K12 + K16 (Abcam, ab10807). 
Rabbit anti-MAP4 (Millipore-Sigma AB6020) was diluted at a ratio of 1:1000. After 
washing the cells in a 24 well plate for 10 minutes at 100 RPM on a Boekel Flask Dancer 
in block solution, the appropriate secondary antibody (Alexa Fluor, Thermo Fisher 
Scientific, Waltham, MA, USA) was applied with a ratio of 1:500 antibody: block for 1h. 
After another wash, cells were stained for DNA with DAPI diluted with PBS/10% FBS 
for 20 minutes. After washing with PBS/10%FBS, cells were mounted on microscope 
slides and imaged using a Nikon Eclipse Ts2R microscope. 
F. Live imaging 
Oocytes and zygotes were transferred to M2 medium, EmbryoMax KSOM+AA 
with D-Glucose culture medium (Millipore, MR-106-D) covered with EmbryoMax Light 
Mineral Oil (Millipore, ES-005-C) and imaged using a Nikon Eclipse Ts2R microscope. 
All live imaging was performed after antibody injection using a 60mm culture dish. 
Images were taken at different time intervals based on developmental stage of oocyte or 
embryo (see respective figures for exact time intervals). 
G. In vitro maturation (IVM) of oocytes 
 GV oocytes were collected as mentioned above and were arrested with 
cilostamide until cell cycle release after all microinjections were completed. GV oocytes 
were washed in M2 medium without cilostamide and KSOM without cilostamide. 
Finally, the oocytes were cultured overnight in KSOM without cilostamide, to the MII 
stage. Live images were taken at 1h after microinjection and the following morning for 
TRIM21-mCherry mRNA confirmation. These samples were then used for western blot. 
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H. Western blot  
MII oocytes from in vitro maturation or from a fresh collection and were 
transferred into 5-8µL of PBS/10% Sample Buffer 2 (lysis buffer) (ProteinSimple, 042-
195), vortexed and centrifuged. Mouse liver serving as a positive control for RBBP4 was 
dissolved in 5µL of PBS/10% Sample Buffer 2, vortexed, and centrifuged. Samples were 
brought to the Alfandari lab (University of Massachusetts Amherst) to run a western blot 
analysis using the Wes machine, which automates traditional western blotting. Anti-
RBBP4 was used to detect if RBBP4 protein was present in MII oocytes while anti-
GAPDH was used as a control to detect GAPDH, a housekeeping gene that will be 
present in all samples. Both antibodies were diluted 1:100 in antibody diluent solution 
(Protein Simple, 042-203). An EZ Standard Pack 1 (Protein Simple, PS-ST01EZ) was 
used to prepare the separation module. 40µL of deionized water was added to the DTT 
tube to make a 400mM solution. 20µL of 10X Samples Buffer 2 and 20µL of the 
previously prepared 400mM DTT solution was added to the 5X Fluorescent Master Mix. 
20µL of deionized water was added to the Biotinylated Ladder tube. The secondary HRP 
conjugate used were rabbit for RBBP4 and mouse for GAPDH, respectively. The 
secondary HRP conjugate for rabbit was diluted as 1:50 since it was previously diluted 
with glycerol. To achieve 1-part 5X Fluorescent Master Mix: 4-parts sample, 2µL of 5X 
Fluorescent Master Mix was added to the 8µL of M2 oocyte sample and 1.2µL of 5X 
Fluorescent Master Mix was added to the 5µL of live sample. All samples were 
denatured at 95ºC for 5 minutes and stored on ice until used. 200µL of Luminol-S and 
200µL of peroxide (ETC) were combined in a microcentrifuge tube and stored on ice 
until use. The top half of the microplate (Cat# SM-W004) was peeled off while leaving 
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the bottom half intact until run time, due to an evaporative gel material. Samples and 
other solutions were loaded into the microplate according to Figure 6 and centrifuged for 
5 minutes at 1000 x g at room temperature. After separating proteins by molecular 
weight, the proteins were immobilized via UV light in a glass capillary tube. They were 
incubated with the respective primary antibody and respective secondary HRP conjugate. 
The chemiluminescence of each sample was quantified by using the ETC. Normal Wes 
run time is about 2-3 hours. 
 
 
Fig 6. Wes Microplate Loading Schematic 
Each reagent and prepared sample will be aliquoted into the appropriate well for 
automatic loading into glass capillaries within the Wes machine. The bottom seal should 
be peeled off directly prior to loading the microplate into the machine due to evaporative 
materials.  
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I. 5-ethynyl uridine (EU) incorporation assay 
The Click-iT RNA Alexa Flour 488 Imaging Kit used (ThermoFisher, C10329) 
was used to detect nascent (newly synthesized) RNA temporally and spatially in 
embryos. This kit was aliquoted in house before use. KSOM medium with 100µM EU 
was equilibrated for 2h in 37 ºC in a humidified atmosphere of 5% CO2, 5% O2 balanced 
in N2. Embryos were then cultured in the same KSOM medium for an additional 2h 
under the same conditions for the alkyne-containing nucleoside (EU) to be incorporated 
into nascent RNA. Embryos were then immediately fixed, permeabilized, and stained 
with either DAPI or with the appropriate primary and secondary antibody, according to 
the manufacturer’s protocols. DAPI was diluted with PBS/3% PVP and embryos were 
washed afterwards using PBS/3% PVP as well. Embryos were then mounted on 
microscope slides and imaged using a Nikon Eclipse Ts2R microscope.  
J. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) 
 Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining 
was performed using the In Situ Cell Death Detection Kit (Roche, 11684795910) as a 
DNA break assay, according to the manufacturer’s protocol. Embryos were collected, 
fixed, and permeabilized as mentioned above. After permeabilization, embryos were 
washed in a 24 well plate for 10 minutes at 100 RPM on a Boekel Flask Dancer in 
PBS/10% FBS. Embryos were moved into the TUNEL reaction mixture containing a 
1:10 mixture of Enzyme Solution (TdT) (Roche, 11684795910) and Label Solution 
(flourescin-dUTP) (Roche 11684795910), protected from light for 30 minutes at 37ºC. 
After washing, embryos were stained with DAPI and washed once more. Embryos were 





A. Generation of mRNA 
 mRNA which would then be injected into the oocyte or embryo was generated 
using the different plasmids listed in Table 1. To validate and linearize the plasmids a 1% 
agarose gel was run (not shown) for confirmation. After each RNA purification, another 
1% agarose gel was run for confirmation (Figure 7). Figure 7A and Figure 7B gels show 
the RNA present within the diluted sample at different points in the plasmid and RNA 
purification processes. The concentration was also measured via a spectrophotometer and 
considered when choosing mRNA to inject. Comparing the concentration of RNA after 
purification in Figure 7A, plasmid #3 (P3) with no Phenol: Chloroform purification 
decreased to 19% RNA present, while the Phenol: Chloroform purified P3 decreased to 
16% RNA present.  Additionally, in Figure 7B the Phenol: Chloroform purified plasmid 
#1 (P1) decreased to 13% RNA present and 24% after RNA Purification. Without some 
form of plasmid purification, successful RNA purification was not consistent in providing 
high concentrations, which can be observed from multiple RNA purification experiments 
previously conducted within the lab (not shown).     
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Fig 7. pGEMHE-mEGFP-mTRIM21 and pGEMHE-mCherry-mTRIM21 RNA 
Purification 
A.) This RNA purification was done with isolated P3 Lane 1 represents the 1KB ladder. 
Lane 2 represents the total RNA after in vitro transcription, but before RNA purification 
(8290 ng/µL). Lane 3 represents the total RNA after IVT and RNA purification (1640 
ng/µL). Lane 4 represents the total RNA after in vitro transcription and plasmid Phenol: 
Chloroform purification, but before RNA purification (9940 ng/µL). Lane 5 represents 
the total RNA after IVT, Phenol: Chloroform plasmid purification and RNA purification 
(1670 ng/µL). B.) This RNA purification was done with isolated P1. Lane 1 represents 
the 1KB ladder. Lane 2 represents the total RNA after in vitro transcription, but before 
RNA purification (8500 ng/µL). Lane 3 represents the total RNA after IVT, Phenol: 
Chloroform plasmid purification, and RNA purification (1140 ng/µL). Lane 4 represents 
the total RNA after in vitro transcription and plasmid Phenol: Chloroform purification 
(6150 ng/µL), but before RNA purification. Lane 5 represents the total RNA after IVT, 
Phenol/Chloroform plasmid purification and RNA purification (1520 ng/µL).  
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B. Trim-Away Methodology Confirmation  
All injected antibodies were purified unless otherwise stated. We first injected 
TRIM21-mEGFP mRNA for overexpression and anti-RBBP4 (unpurified) 
simultaneously into GV oocytes (Figure 8). After fixation and immunofluorescence, it 
was clear that TRIM21-mEGFP was not overexpressed within these oocytes and 
consequently, the RBBP4 protein was not depleted from the nucleus. Unsure as to the 
cause of this (RNA or antibody related) we wanted to test the quality of our RNA. We 
conducted separate injections of mRNA and antibody (Figure 9). GV oocytes were 
injected with TRIM21-mEGFP mRNA and after a waiting period of 3h, anti-RBBP4 
(unpurified) was injected. After fixation and immunofluorescence, TRIM21-mEGFP was 
overexpressed, but the RBBP4 protein was still not depleted from the nucleus. These 
results show there was no significant difference between the negative control (un-
injected) and the anti-RBBP4 injected GV oocytes and that our mRNA quality is optimal 






Fig 8. Co-injection of TRIM21 mRNA and Anti-RBBP4 in GV Oocytes 
3 hours after a co-injection of pGEMHE-mEGFP-mTRIM21 and anti-RBBP4, GV 
oocytes were fixed. Immunofluorescence was conducted to observe the concentration of 




Fig 9. Separate Injections of TRIM21 mRNA and Anti-RBBP4 in GV Oocytes 
Anti-RBBP4 was injected 3 hours after injection of mRNA from pGEMHE-mEGFP-
mTRIM21. GV oocytes were incubated at 37ºC for 3 hours and then fixed. 
Immunofluorescence was conducted to observe the concentration of TRIM21 mRNA and 
RBBP4 protein present. Anti-RBBP4 was not purified. 
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To test our Trim-Away methodology, we chose to look at 2 different proteins at 
the MII oocyte stage, H2B and MAP4. We first looked at H2B. H2B was overexpressed 
with H2B-mEGFP mRNA along with TRIM21-mCherry overexpression 3h before anti-
H2B (unpurified) was injected (Figure 10). These oocytes were live imaged for 120 
minutes after antibody injections. There was a depletion of H2B protein and TRIM21-
mCherry at 30 minutes. After 30 minutes the H2B protein and TRIM21-mCherry 
expression returned. To see if the H2B protein could be trimmed away if allotted a longer 
culture time, we repeated the previously mentioned experiment of overexpressing H2B 
with H2B-mEGFP mRNA along with TRIM21-mCherry overexpression 3h before anti-
H2B was injected (Figure 11). We saw that at 40 minutes, the H2B protein was depleted 
once again, but when these MII oocytes were incubated overnight, the H2B protein and 
TRIM21-mCherry signal returned with an even stronger concentration than there was 
previously at the 40-minute mark. In addition, we conducted Trim-Away using TRIM21-
mCherry anti-H2B in zygotes and at each allotted time a live image was taken (Figure 
12). During the zygote and 2-cell stage, there was little to no depletion seen in anti-H2B 




Fig 10. Trim Away of H2B Using Unpurified Anti-H2B in MII Oocytes   
Anti-H2B was injected 3 hours after injection of mRNA from pGEMHE-mEGFP-
mTRIM21 and H2B-mEGFP. MII oocytes were live imaged to observe the concentration 
of TRIM21 mRNA and H2B protein present. There was a depletion of H2B protein at 30 




Fig 11. Trim Away of H2B Using Purified Anti-H2B in MII Oocytes  
Anti-H2B was injected 3 hours after injection of mRNA from pGEMHE-mEGFP-
mTRIM21 and H2B-mEGFP. MII oocytes were live imaged to observe the concentration 
of TRIM21 mRNA and H2B protein present. There was a depletion of H2B protein at 40 
minutes. Anti-H2B was purified. 
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Fig 12. Trim Away of H2B Using Purified Anti-H2B in Zygotes and 2-cell Embryos 
Anti-H2B was injected 3 hours after injection of mRNA from pGEMHE-mEGFP-
mTRIM21 and H2B-mEGFP. Zygotes and 2-cell embryos were fixed, and 
immunofluorescence was conducted to observe the concentration of TRIM21 mRNA and 
H2B protein present. little to no depletion was seen using Anti-H2B in zygotes or 2-cell 




Taking another look at the original Trim-Away paper from Clift and colleagues, 
while overexpressing H2B and MAP4, they rabbit anti-GFP (Abcam, ab6556) as their 
antibody of choice against both proteins [35]. When we compared injecting anti-H2B to 
injecting anti-GFP 3h after H2B-mEGFP and TRIM21-mCherry overexpression, there 
was a significant difference in the long-term depletion of the H2B protein (Figure 13). 
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We also focused on MAP4 protein and TRIM21-mCherry overexpression (Figure 14). 
MAP4 overexpression was conducted using MAP4-mEGFP mRNA. At the 10-minute 
and 80-minute mark, there was little to no difference between each group. This was most 
likely due to low MAP4 mRNA concentrations. We allowed these oocytes to incubate 
overnight for a clearer conclusion if Trim-Away occurred. With the overnight incubation, 
the anti-GFP and anti-MAP4 group had clear depletions of MAP4 protein compared to 
the RNA Only and Rb IgG injected groups. These results suggest that anti-Map4 was 
sufficient in depleting the MAP4 protein, but anti-GFP was optimal for a greater 




                    
Fig 13. Trim Away of H2B Using Purified Anti-H2B and Purified Anti-GFP 
Either Anti-H2B or Anti-GFP was injected 3 hours after injection of mRNA from 
pGEMHE-mEGFP-mTRIM21 and H2B-mEGFP. MII Oocytes were live imaged to 
observe the concentration of TRIM21 mRNA and H2B protein present. There was a 
depletion of H2B protein at 120 minutes using Anti-H2B. Anti H2B and Anti-GFP were 
purified. 
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Fig 14. Trim-Away of MAP4 Using Purified Anti-MAP4 and Purified Anti-GFP 
Either Anti-MAP4 or Anti-GFP was injected 3 hours after injection of mRNA from 
pGEMHE-mEGFP-mTRIM21 and MAP4-mEGFP MII Oocytes were live imaged to 
observe the concentration of TRIM21 mRNA and MAP4 protein present. There was a 
depletion of MAP4 protein at 80 minutes using both Anti-MAP4 and Anti-GFP. There 
was long lasting depletion when injecting either Anti-Map4 or Anti-GFP, but GFP had 





C. Trim-Away in Embryos  
Since our methodology was confirmed, we moved forward and focused on our target 
protein, RBBP4. Continuing to use TRIM21-mCherry overexpression, we then injected 
anti-RBBP4 into zygotes 3h later. The zygotes were cultured for 3h or overnight for 
development into 2-cell embryos (Figure 15A). Anti-RBBP4 injected zygotes cultured 3h 
after their antibody injection had no depletion of RBBP4. There was a clear nuclear 
signal for RBBP4 still present. Zygotes that were cultured until the 2-cell stage had a no 
nuclear signal for RBBP4 within the nucleus (Figure 15B).  
The antibody used for the Rb IgG control embryos was not purified for this 
experiment. The cytoplasm within the RNA Only injected embryos, Rb IgG injected 
embryos, and anti-RBBP4 injected embryos, had a higher cytoplasmic signal than the 
nothing control (un-injected) embryos. This is because both injected antibody (Rb IgG or 
Rb Anti-RBBP4) and TRIM21 can both bind to the secondary ani-rabbit antibody during 
IF. 
This RBBP depletion from the 2-cell stage lasted through 4 and 8-cell embryos 
(Figure 15C and 15D), along with morula and blastocysts as well (Figure 15E and 15F). 
All embryos at each stage and each group had similar normal phenotypes expect those in 
the Anti-RBBP4 injected group at the blastocyst stage Figure 16. Our Anti-RBBP4 
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injected embryos also had a slower development overall compared to the negative control 
(not shown). When there was a depletion of RBBP4 only 1% of blastocysts developed 
properly from the morula stage. This 1% most likely represented embryos which had an 
unbalanced ratio of the 3 components needed for Trim-Away (TRIM21, antibody, and 
target protein). With each repeat of Trim-Away using anti-RBBP4 injections, there were 
successful depletions of RBBP4 starting from the 2-cell stage through the blastocyst 
stage. These results suggest that RBBP4 can be trimmed away as early as the 2-cell stage. 
It also suggests that with sufficient injected TRIM21- mRNA and antibody, RBBP4 will 





















Fig 15A-F. Trim-Away of RBBP4 At All Preimplantation Embryo Development 
Stages 
Anti-RBBP4 was injected 3 hours after injection of mRNA from TRIM21-mCherry . 
Zygotes were cultured until each developmental stage above was reached and fixed. 
Immunofluorescence was conducted to observe the concentration of TRIM21 mRNA and 
RBBP4 protein within each cell. At the zygote stage, there is a clear nuclear signal for 




Fig 16. Blastocyst Phenotype 
RNA Only and Rb IgG groups formed a blastocoel at the early blastocyst stage. All Anti-
RBBP4 injected group were unable to form a blastocoel and had abnormal phenotypes at 
the early blastocyst stage. 
 
D. Total Nascent RNA 
The depletion of RBBP4 through Trim-Away is clear within the embryo starting 
at the 2-cell stage, and therefore may be affecting different mechanisms within the cell 
such as transcription and ZGA. To investigate this, we utilized an EU incorporation assay 
to detect nascent RNA (Figure 17). DNA contains nucleobases such as thymine, guanine, 
cytosine, and adenine while RNA contains uridine instead of thymine. Within this EU 
assay, the modified 5-ethynyl uridine (EU) will be incorporated into nascent RNA 
replacing the natural uridine [46]. The modified nascent RNA will then be detected by 
the chemoselective ligation reaction between the azide and alkyne. This reaction is 
detected with the corresponding azide-containing dye (green, fluorescent color). There 
was little difference in nuclear RNA signal at the 4-cell and 8-cell stage (not shown) from 
anti-RBBP4 injected embryos compared to our controls of un-injected, RNA Only, and 
Rb IgG injected embryos. At the 2-cell and Morula stages, un-injected (not shown), RNA 
Only (not shown), and Rb IgG injected embryos showed high RNA transcription signal 
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within the nucleus, while anti-RBBP4 injected embryos show much less nuclear signal. 
These results suggest that RBBP4 has a function in ZGA at the 2-cell stage or gene 
transcription in later embryo development ZGA.  
The EU assay allows for the use of additional probes, such as antibodies. We 
stained for H4ac and residues (K5, K8, K12, and K16) (Abcam, ab177790). There was no 
clear difference between control groups and the Anti-RBBP4. Even within each group 
there were varied signals for H4ac, meaning there will have to be additional studies done 






Fig 17. EU Incorporation Assay Analysis 
Anti-RBBP4 was injected 3 hours after injection of mRNA from TRIM21-mCherry . 
Zygotes were incubated at 37ºC for until each developmental stage above was reached 
and were then incubated in KSOM incorporated with EU for 2h. Embryos were 
immediately fixed and incubated with reaction buffers listed previously. In addition to the 
EU incorporation, immunofluorescence was conducted to observe the concentration of 




E. Total Cell Death 
The loss of RBBP4 in early embryo development affects successful blastocyst 
formation and therefore may be caused by high cell death at the Morula stage. To 
investigate this, we utilized an In Situ Cell Death Detection Kit (Figure 18). This kit is a 
precise, fast, and simple nonradioactive technique to detect and quantify apoptotic cell 
death from a molecular level (DNA breaks). DNA breaks were detected with the 
corresponding label solution (green, fluorescent color). Although this kit is sensitive and 
aims to reduce background labeling, there was still some background, which is 
represented by the cytoplasm. At the morula stage, RNA Only embryos and Rb IgG 
embryos were similar in the amount of cell death present. RNA Only embryos have non-
specific binding within their nuclei and cytoplasm along with apoptotic polar bodies and 
one sperm that was able to penetrate the ZP, but not the zygote itself. Rb IgG embryos 
also have non-specific binding within the cytoplasm and most of the nuclei, with the 
exception of only a few nuclei showing the apoptotic signal. Anti-RBBP4 injected 
embryos had significantly more apoptotic cells especially within most, if not all, nuclei. 





Fig 18. TUNEL of Morula Stage Embryos  
Anti-RBBP4 was injected 3 hours after injection of mRNA from TRIM21-mCherry . 
Zygotes were incubated at 37ºC for until the morula stage. Embryos were immediately 
fixed and incubated with the enzyme solution and label solution.  
 
 
F. Trim-Away in Oocytes  
Previously, a group from Rutgers University studied the loss of RBBP4 in oocyte 
maturation utilizing an siRNA knockdown (KD). To achieve their KD, they arrested GV 
oocytes for 12-15 hours. We hypothesized that maybe Trim-Away would be able to 
deplete RBBP4 earlier than 12-15 when arrested at the GV oocytes stage. Testing this 
hypothesis, we arrested GV oocytes overnight and saw a small depletion from our group 
that was fixed after 3h of culture (Figure 19). This slight depletion was most likely due to 
natural long-term degradation which happens when the freshy made protein is not 
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shuttled into the nucleus from the cytoplasm because it is being trimmed away 
immediately by the overexpressed TRIM21 in the cytoplasm. Additionally, our Rb IgG 
group increased in RBBP4 signal overnight, which was likely due to the cell cycle arrest 









Fig 19. Trim-Away of RBBP4 Using Anti-RBBP4 in Arrested GV Oocytes 
Anti-RBBP4 was injected 3 hours after injection of mRNA from pGEMHE-mEGFP-
mTRIM21. GV oocytes were cultured for either 3 hours or overnight and then fixed. 
Immunofluorescence was conducted to observe the concentration of TRIM21 mRNA and 




We then wanted to investigate the possibility of depleting RBBP4 at different 
stages once the oocytes matured in vitro. First, a western blot needed to be run to 
determine if RBBP4 was present at the MII stage since it is not detectable by IF alone. 
Un-injected MII oocytes were ran using a Wes machine in the Alfandari lab. The 
Alfandari lab’s main model organism is Xenopus, so a test was conducted to quantify 
how many mouse oocytes would be necessary to see the RBBP4 protein. Serial dilutions 
were conducted so that in Figure 20, Lane 5 contained 78 oocytes (1X), Lane 6 contained 
39 oocytes (1/2X), and Lane 7 contained 19.5 oocytes (1/4X). The least amount of mouse 
oocytes which can be used for running the Wes machine without a long exposure time is 
around 39 oocytes, representative in Lane 6. Mouse liver was also used as a positive 
control for RBBP4. GAPDH, a positive control for all samples and housekeeping gene, 
was detected in all samples with the proper number of cells (all lanes shown). These 
results suggest that RBBP4 is present within the MII stage oocyte and that RBBP4 is 






Fig 20. Western Blot for RBBP4 Confirmation  
Lane 2-4 represent MII oocytes in serial dilutions from 78 oocytes to 39 oocytes, to 19.5 
oocytes detecting for RBBP4 protein. Lane 5-7 represent MII oocytes in serial dilutions 
from 78 oocytes to 39 oocytes, to 19.5 oocytes detecting for GAPDH protein. Lane 8-9 
represents liver cells serial dilutions from the full sample to 1/10th of the sample, 
detecting for RBBP4 protein. Lane 8-9 represents liver cell serial dilutions from the full 
sample to 1/10th of the sample, detecting for GAPDH protein. GAPDH represents the 





After confirming the necessary number of oocytes to properly run the Wes at a 
short exposure time, we then collected GV oocytes and co-injected injected TRIM21-
mCherry and either anti-RBBP4, Rb IgG, or nothing for a negative control. Co-injection 
was previously tested within our embryo model because there was a clear depletion with 
separate injections (not shown). Once we confirmed co-injection trimmed away RBBP4, 
we conducted these injections into GV oocytes for either 3.5h to the GVBD stage or 
overnight to the MII stage and then transferred into lysis buffer for a western blot to be 
ran (Figure 21). Within this western blot, we used a secondary antibody that recognizes 
the light chain of our injected antibodies, due the possibility of the previous secondary 
antibody recognizing the injected antibody around the same molecular weight as our 
RBBP4 protein. The injected antibody will be detected at 25 kDa instead of 50 kDa.  
Our GAPDH tested samples showed unclear bands of where GAPDH was located 
on the molecular weight scale. This was most likely due to the antibody being old or 
unspecific binding from a long exposure time of the blot. Based on which band is 
confirmed as GAPDH, our Trim-Away results could change. We also see that there is a 
shift in protein molecular weight in the MII stage, most likely due to RBBP4 being 
phosphorylated or compacted in some way.  
Although we cannot come to a clear conclusion whether RBBP4 was depleted in 
our GVBD or MII oocytes, we can see that at the MII stage there is about 3-fold more 
endogenous RBBP4 protein present than in GVBD oocytes. This was quantified using an 
electropherogram where GVBD had around a 400 chemiluminescent substrate 
concentration while MII oocytes had around a 1200 concentration. Using an 
electropherogram we can quantify lanes 2,3,4, and 5 form the previous western blot 
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(Figure 22). RBBP4 protein was present within all samples that contained oocytes (seen 
at 55 kDa). The black peak shown at 55 kDa represents the sample with no oocytes 
present and confirms the specificity of the Wes machine for detecting RBP4 protein. The 
light chain of the detected injected antibodies can be seen at 25 kDa and is present in all 
samples with antibody, except our Anti-RBBP4 injected group. There is a small peak 
represented showing that there was anti-RBBP4 was present, which suggests that either 
there was a low concentration of antibody injected and it was not sufficient to deplete 





Fig 21. Western Blot for Trim-Away During Oocyte Maturation 
All samples containing oocytes used 10 oocytes. Lane 1 represents the biotinylated 
ladder. Lanes 2-15 represent RBBP4 stained samples. Lanes 16-25 represent GAPDH 
stained lanes. GAPDH represents the positive control for each sample showing there are 
cells present for each sample provided. Within lanes 2-6 and 12-20, oocytes were 
matured from the GV stage to the GVBD stage. Within lanes 7-11 and 21-25 oocytes 







Fig. 22 Electropherogram Quantification  
The blue peaks represent un-injected oocytes, green represents Rb IgG injected oocytes, 
red represents anti-RBBP4 injected oocytes, and black represents our lysis buffer mixed 
with antibody only. All samples have RBBP4 protein present except the lysis buffer with 
antibody only (55 kDa). All samples with injected antibody show the antibody present at 













As previously shown in different studies, RBBP4 is essential for oocyte 
maturation and embryo development. Specifically in oocyte maturation, RBBP4 is 
essential for histone deacetylation, while in embryo development it is essential for proper 
segregation of the ICM and TE, and for proper implantation [22, 23]. In many loss of 
function studies, techniques such as CRISPR/Cas9 and RNAi are used. Unfortunately, 
these techniques have limitations such as determining an indirect depletion of proteins 
and the possibility of triggering compensatory mechanisms. A new, acute, and rapid 
protein depletion method called Trim-Away offers a method to overcome these 
limitations [34].   
 Trim-Away utilizes the TRIM21-antibody interaction to target a protein for 
degradation. Once all 3 components are bound together, the complex is ubiquitinated and 
dragged to the proteasome for degradation. Trim-Away allows for the depletion of 
endogenous proteins without the need for prior modification of the protein-coding gene 
or mRNA [35]. For nuclear proteins, Trim-Away has been seen to accomplish 
degradation soon after at least one cell division and the TRIM21 mRNA can last for as 
long as 3-4 days [15]. This technique is flexible and should be able to be applied to any 
mammalian species. It is also widely applicable due to its ability to be used with many 
off-the-shelf reagents [35].  
One of the most challenging aspects of this project for our lab was the RNA 
purification process. One critical consideration we did not account for at first was 
RNases, hydrolytic enzymes that degrade RNA and how easily they can accomplish 
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this[47, 48]. RNases can be found within solutions, consumables, and labware, and can 
impact any experiment involving RNA such as in vitro transcription (IVT), RNA 
purification, Ribonuclease Protection Assays (RPAs), and Northern Blots [49]. There are 
many steps one can take to avoid RNA degradation.  
Plasmid purification via Phenol: Chloroform can be useful during the RNA 
purification processes. Phenol: Chloroform purification of nucleic acids denatures 
proteins and collects the organic phase (interphase) for use in RNA purification. The 
Phenol: Chloroform protocol used from Thermo Fisher has been tested and no RNase or 
DNase activity was detected [49]. This protocol provided us with successful and 
consistent results of plasmid purification. Our RNA purification results with plasmid 
purification compared to unpurified plasmids were drastically different and more 
consistent in providing high concentrations of purified RNA, so the decision to always 
purify plasmids via Phenol: Chloroform before IVT was made.  
Additionally, RNase activity can be limited by RNaseZap, an RNase 
Decontamination Solution (ThermoFisher, AM9782). This solution is sprayed onto glass 
and plastic surfaces to decontaminate and destroy RNases on contact. RNaseZap has been 
proven to be more effective at removing high levels of RNase contamination than other 
products and can be applied to microcentrifuge tubes without inhibiting subsequent 
enzymatic reactions, which is why we choose this product to eliminate RNases [48].  
RNA purification also relies on high graded ethanol for adding into the samples and 
for precipitation. The MEGAclear Transcription Clean-Up Kit we used, requires 100% 
ethanol (ACS grade or better). With the combination of our plasmid purification, 
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spraying RNaseZap onto our workspaces, and new ACS grade ethanol, we were able to 
successfully repeat multiple RNA purifications for mRNA injections.  
 Even though our microinjection machinery is high end, there is no way to inject 
the exact same amount of mRNA each time, we can only aim for this which contributed 
to the different TRIM21 overexpression signals we see throughout all figures in this 
thesis. As far as degradation of each component goes, all 3 components in the Trim-
Away mechanism, TRIM21, antibody, and the endogenous target protein, will be 
degraded by the proteasome [50]. Additionally, our mRNA that was first being injected 
for separate injections (mRNA then antibody 3h later) was at a concentration of 750 
ng/µL. We realized this high concentration was not feasible for proper embryo 
development, and subsequently lowered our mRNA concentration by diluting our 
samples with nuclease-free water. We found that around 300 ng/µL for separate mRNA 
and antibody injections allowed proper embryo development. Our co-injection 
experiments consisted of injecting half mRNA and half desired antibody simultaneously, 
which meant we needed to increase the mRNA concentration to 600 ng/µL. 
 Co-injections for GV oocytes did not provide sufficient depletion of RBBP4 in 
the beginning of this project. At first, our co-injection experiments showed no TRIM21 
protein translated from the injected mRNA. We hypothesized this was either due to our 
mRNA quality or due our commercial antibody for RBBP4 [51]. After conducting a run 
of GV oocyte separate injections, we confirmed it was not our mRNA quality, but due to 
our antibody. Purification of anti-RBBP4 was completed and injected into GV oocytes 3h 
after mRNA with similar results of no RBBP4 depletion. Based on the original Trim-
Away paper by Clift and colleagues, at least one cell division cycle must occur to allow 
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the degradation of retained nuclear target proteins [50]. When at least one cell cycle 
division was considered for embryo development, RBBP4 was depleted as early as the 2-
cell stage. Within future experiments it may be useful to utilize nanobodies for the 
depletion of nuclear proteins if no cell division will occur for arrested GV oocytes. The 
Fc domain of our commercial antibody would be fused to the nanobody for TRIM21 to 
bind to, and the nanobody would be able to infiltrate the nucleus without nuclear 
membrane breakdown [35]. 
 Previously, the Cui Lab collaborated with Dr. Jesse Mager’s Lab (University of 
Massachusetts Amherst) to study RBBP4 using a KO model and determined RBBP4 was 
important for embryo development [23]. Since RBBP4 is a lethal gene, a heterozygous-
by-heterozygous breeding scheme was needed and there was always maternally loaded 
RBBP4 mRNA and protein. It was not until 3 days after blastocyst collection, during the 
outgrowth phase, did we see an abnormal phenotype in the KO embryos. Here we report 
that there was a depletion of RBBP4 by the 2-cell stage that causes an abnormal 
phenotype at the early blastocyst stage. Studying the depletion of RBBP4 via Trim-Away 
has an advantage over the CRISPR/Cas9 KO model used since it can cause an earlier, 
more severe phenotype and overcome the above mentioned maternal loading limitation.  
 Using an EU Incorporation Assay and a TUNLEL Assay, we investigated the 
reason behind our abnormal blastocyst development. Sha and colleagues used a similar 
EU Assay to measure the amount of nascent RNA by using Trim-Away for protein 
depletion of BTG4. This group did not see any changes in RNA synthesis within the 
Trim-Away of BTG4 at the 2-cell stage [52]. Our Trim-Away model for depletion of 
RBBP4 showed a significant decrease in nascent RNA at the 2-cell and morula embryo 
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stages, compared to the clear signal in the control groups of RNA only and Rb IgG 
injection. This suggests that RBBP4 has a function in either ZGA or gene transcription in 
later stages of embryo development. Through a TUNEL Assay, Miao and colleagues saw 
an increased apoptotic signal within their homozygous KO embryos at the blastocyst 
stage [23]. Similarly, in our TUNEL Assay, we saw a significant increase in apoptotic 
cell within the morula stage within our anti-RBBP4 injected group and the control RNA 
Only and Rb IgG groups, suggesting that RBBP4 has a role in DNA repair during early 
embryogenesis. 
 Within many experiments, the cytoplasm brightness of Rb IgG injected embryos 
overlayed, or dulled, the RBBP4 nuclear signal. We hypothesized this was due to the Rb 
IgG binding our secondary antibody (anti-rabbit) within the IF process. We saw similar 
cytoplasmic brightness within the RNA Only group and hypothesized this was due to 
TRIM21 binding to the secondary antibody during IF as well. Through a trial run of 
injecting less Rb IgG and less TRIM21 mRNA, we discovered that both the injected 
antibody and TRIM21 can bind to the secondary antibody during IF, causing this high 
cytoplasmic signal. Additionally, any “leftover” injected anti-RBBP4 that was not 
degraded by the proteasome when Trim-Away machinery depleted the RBBP4 protein, 
also could bind to the secondary antibody of IF.  
  Although an endogenous RBBP4 signal is visible at all stages of embryo 
development, this is not the case for mouse oocyte maturation. During oocyte maturation 
RBBP4 signal is visible via IF at the GV stage, while at the MI and MII stages it is not 
[22]. This is most likely due to RBBP4 modification within the oocyte at these stages. 
RBBP4 being localized to the chromatin and being found in many other protein 
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complexes such as the HDAC, NuRD, and PCR2 could have an impact on this [24-26]. 
There is a possibility RBBP4 may be phosphorylated or compacted in a way such that our 
commercial antibody cannot detect the protein’s immunogen. Commercial antibodies 
bind to a specific immunogen from a POI. Our anti-RBBP4 specifically binds to human 
RBBP4 amino acids 1-100 (N terminal) and is reactive with mouse, rat, and human [51]. 
It is possible RBBP4 may be undetectable within rat and human MI and MII oocytes as 
well. Similarly, in our H2B experiments, H2B was not detected through IF at the MII 
stage and was not depleted long term through Trim-Away either. This was most likely 
due to the same reason of this protein being modified, for example phosphorylated, or 
compacted in a way it was not able to bind to our commercial antibody for H2B but could 
bind to our GFP antibody. The MAP4 protein did not seem to have this issue when 
trimming away during the MII oocyte stage and could be trimmed away with either anti-
MAP4 or anti-GFP.  
To overcome the limitation of RBBP4 not being detectable by IF, a western blot 
was run via the Wes machine in the Alfandari lab (University of Massachusetts Amherst) 
and confirmed RBBP4 was present within the MII oocyte stage and was more abundant 
in female germ cells compared to liver somatic cells. Through western blot experiments 
we discovered that RBBP4 was not fully depleted in oocytes and that there is a possibility 
RBBP4 is too abundant at these stages for the concentration of antibody we injected. 
There was also a shift in molecular weight most likely due to this modification on 
RBBP4. With the RBBP4 concentration shown in each band, we concluded RBBP4 was 
about 3-fold higher in MII oocytes than GVBD oocytes. Within future experiments we 
hope to find the reason our protein was not full depleted in oocytes and then hopefully 
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both embryo and oocyte Trim-Away models can be applied to many other species or 
eventually aid in human health.  
In conclusion our results showed that RBBP4 is required for proper blastocyst 
development and RBBP4 is more abundant in MII oocytes than GVBD oocytes. We also 
report that the loss of RBBP4 hinders RNA synthesis and causes cell death in later stages 
of embryo development. Lastly, while our Trim-Away methodology can deplete RBBP4 
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